Corient Private Wealth LLC Makes New $109,000 Investment in Kura Oncology, Inc. (NASDAQ:KURA)

Corient Private Wealth LLC acquired a new stake in Kura Oncology, Inc. (NASDAQ:KURA – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,490 shares of the company’s stock, valued at approximately $109,000.

Other large investors have also made changes to their positions in the company. E Fund Management Co. Ltd.



acquired a new position in Kura Oncology in the 4th quarter valued at $90,000. China Universal Asset Management Co. Ltd.

grew its position in shares of Kura Oncology by 11.9% in the fourth quarter. China Universal Asset Management Co.

Ltd. now owns 16,489 shares of the company’s stock valued at $144,000 after purchasing an additional 1,750 shares during the period. Point72 DIFC Ltd acquired a new position in Kura Oncology in the third quarter valued at $146,000.

AlphaQuest LLC acquired a new position in Kura Oncology in the fourth quarter valued at $177,000. Finally, US Bancorp DE lifted its position in Kura Oncology by 184.5% during the fourth quarter.

US Bancorp DE now owns 22,104 shares of the company’s stock worth $193,000 after buying an additional 14,335 shares during the period. Kura Oncology Trading Up 2.2 %Shares of NASDAQ:KURA opened at $6.

52 on Thursday. The company has a 50 day moving average of $7.76 and a 200-day moving average of $11.

71. The company has a current ratio of 11.47, a quick ratio of 11.

47 and a debt-to-equity ratio of 0.02. The firm has a market cap of $526.

52 million, a P/E ratio of -2.76 and a beta of 0.83.

Kura Oncology, Inc. has a twelve month low of $6.27 and a twelve month high of $23.

48. Kura Oncology (NASDAQ:KURA – Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.

22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.43.

The business had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million.

As a group, analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Analysts Set New Price TargetsKURA has been the subject of several research analyst reports. Scotiabank dropped their price target on Kura Oncology from $18.00 to $10.

00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Kura Oncology in a research note on Thursday, February 27th.

Wedbush reaffirmed an “outperform” rating and set a $36.00 price target on shares of Kura Oncology in a research report on Thursday, February 27th. JMP Securities reiterated a “market outperform” rating and issued a $28.

00 price target on shares of Kura Oncology in a report on Thursday, February 6th. Finally, Cantor Fitzgerald upgraded Kura Oncology to a “strong-buy” rating in a research note on Tuesday, March 4th. Three analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock.

Based on data from MarketBeat, Kura Oncology presently has a consensus rating of “Moderate Buy” and an average price target of $25.50.Read Our Latest Stock Report on KURAInsider Transactions at Kura OncologyIn related news, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction that occurred on Tuesday, January 28th.

The stock was sold at an average price of $7.87, for a total value of $38,948.63.

Following the transaction, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. This represents a 5.

31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction on Tuesday, January 28th.

The shares were sold at an average price of $7.87, for a total transaction of $39,058.81.

Following the completion of the sale, the insider now directly owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. The trade was a 5.

32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock valued at $92,307 over the last three months.

5.50% of the stock is owned by corporate insiders. Kura Oncology Profile (Free Report)Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.

The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.Read MoreFive stocks we like better than Kura OncologyWhat to Know About Investing in Penny StocksHomebuilders in Freefall: Bargain Opportunity or Falling Knife?The Basics of Support and ResistanceThe 3 Most Talked About Investments on WallStreetBets Right NowNatural Gas Prices Continue To Rally, These Stocks Should BenefitAnalyst Targets Signal More Growth in CrowdStrike Stock.